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dDepartment of Occupational Medicine and Public Health, Faroese Hospital System, Torshavn, Faroe Islands; eDepartment of Biostatistics,
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ABSTRACT
Perfluorinated alkylate substances (PFASs) are highly persistent and may cause immunotoxic effects. PFAS-
associated attenuated antibody responses to childhood vaccines may be affected by PFAS exposures dur-
ing infancy, where breastfeeding adds to PFAS exposures. Of 490 members of a Faroese birth cohort, 275
and 349 participated in clinical examinations and provided blood samples at ages 18 months and 5 years.
PFAS concentrations were measured at birth and at the clinical examinations. Using information on dur-
ation of breastfeeding, serum-PFAS concentration profiles during infancy were estimated. As outcomes,
serum concentrations of antibodies against tetanus and diphtheria vaccines were determined at age 5.
Data from a previous cohort born eight years earlier were available for pooled analyses. Pre-natal expos-
ure showed inverse associations with the antibody concentrations five years later, with decreases by up to
about 20% for each two-fold higher exposure, while associations for serum concentrations at ages
18 months and 5 years were weaker. Modeling of serum-PFAS concentration showed levels for age
18 months that were similar to those measured. Concentrations estimated for ages 3 and 6 months
showed the strongest inverse associations with antibody concentrations at age 5 years, particularly for tet-
anus. Joint analyses showed statistically significant decreases in tetanus antibody concentrations by
19–29% at age 5 for each doubling of the PFAS exposure in early infancy. These findings support the
notion that the developing adaptive immune system is particularly vulnerable to immunotoxicity during
infancy. This vulnerability appears to be the greatest during the first 6 months after birth, where PFAS
exposures are affected by breast-feeding.
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Introduction
Industrial chemicals are not routinely tested for immunotoxicity,
but recent evidence suggests that some environmental chemicals
may harm immune functions, perhaps in particular during early
development of the adaptive immune system (Dietert and Dewitt
2010; Dietert 2014). Among recently confirmed immunotoxi-
cants, the perfluorinated alkylate substances (PFASs) have been
widely applied for a multitude of purposes, and due to their per-
sistence, human PFAS exposures now occur globally (Lindstrom
et al. 2011). Women eliminate PFASs via lactation (Mondal et al.
2014), and a child’s exposure in infancy is strongly affected by
transfer via human milk (Liu et al. 2011; Mogensen et al. 2015b).
With human milk being a main source of exposure early post-
natally, serum-PFAS concentrations in infancy could potentially
be estimated from the exposure level at birth and the duration of
breastfeeding.
Experimental evidence so far supports the possibility that early
development of the adaptive immune system may be particularly
vulnerable to PFAS exposure (Dietert 2014), but the U.S.
National Toxicology Program recently concluded that specific
immune cell vulnerabilities and their dependence upon
developmental stages are unclear so far (National Toxicology
Program 2016). Unfortunately, epidemiology studies of toxicant
exposures in infancy are problematic due to the difficulty in
obtaining blood samples from small children.
In addition, immune function tests are not easily applied in
epidemiological studies of small children. However, serum-anti-
body concentrations induced by routine immunizations have
been recommended for this purpose (van Loveren et al. 1999)
due to the advantage that a vaccination constitutes a well-defined
stimulation of the adaptive immune system (Ljungman 2013).
The first vaccinations in infancy stimulate the virgin immune
system, and subsequent re-vaccinations trigger the primary reper-
toire and response as well as secondary responses (Capua et al.
2013). The immune response against specific protein antigens
(such as tetanus and diphtheria toxoids) thereby reflects a variety
of functions, such as antigen presentation, antigen processing, T-
cell help, B-cell activation, germinal center B-cell reactivation,
and B-cell maturation (Schatz et al. 1998).
Recent studies relied on serum concentrations of antibodies
specifically directed against vaccines that were administered in
infancy (Grandjean et al. 2012; Granum et al. 2013), but none of
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them attempted to link the PFAS-associated decreases in anti-
body concentrations to past exposures during infancy. As a siz-
able proportion of fully-vaccinated children may have vaccine
responses that provide incomplete protection against the disease
(Grandjean et al. 2012), PFAS immunotoxicity may be of sub-
stantial public health relevance in regard to the specific vaccine
responses and possibly also in regard to other immune functions.
The present study extends earlier reports on inverse associa-
tions between serum concentrations of PFASs and vaccine-
specific antibodies in children (Grandjean et al. 2012; Mogensen
et al. 2015a), now in a new prospective birth cohort in the Faroe
Islands (Cohort 5, born in 2007–2009). Serum samples from ages
18 months and five years were analyzed for PFASs, and serum-
PFAS concentrations during infancy were modeled. To increase
the statistical power of the study, joint statistical analyses were
conducted with a previous birth cohort (Grandjean et al. 2012),
where PFAS exposures were higher.
Methods
Study population
The Faroese Cohort 5 of 490 children was recruited from births
at the National Hospital in Torshavn, Faroe Islands, during
2007–2009 (Kim et al. 2014; Timmermann et al. 2017). A mater-
nal serum sample was collected about two weeks after the
expected term date. As part of the government-supported health
care system, Faroese children receive vaccinations against diph-
theria and tetanus at ages 3 months, 5 months, and 12 months,
and a booster at age 5 years. This way, the same amount of vac-
cine and associated alum adjuvant was applied at the same ages.
In this population, PFAS exposures are associated with marine
food contamination (Weihe et al. 2008), and these substances do
not occur as contaminants of local drinking water (Eriksson
et al. 2013).
All cohort members were invited for clinical follow-up at ages
18 months and 5 years (before the age-5 booster), where mater-
nal interview, physical examination of the child, and blood sam-
pling took place. Detailed vaccination records were available, as
were obstetrics information, and questionnaire information on
duration of breastfeeding, past medical history and current health
status. In order to increase the statistical power, this study
included data from the earlier Cohort 3 (born 1997–2000), which
had formed the basis of previous reports (Grandjean et al. 2012;
Grandjean and Budtz-Jorgensen 2013; Mogensen et al. 2015a).
Apart from being about eight years apart and therefore differing
in exposure levels and profiles (median concentrations of PFHxS,
PFOS, PFOA, and perfluorodecanoate (PFDA) were lower in
Cohort 5, while the concentrations of perfluorononanoate
(PFNA) were slightly higher compared to Cohort 3), the two
cohorts are highly similar, and methods were virtually identical
(Cohort 3 sampled maternal blood in late pregnancy) (Dalgard
et al. 2016; Timmermann et al. 2017).
The study protocol was approved by the Faroese ethical
review committee and by the institutional review board at
Harvard T.H. Chan School of Public Health. Written informed
consent was obtained from all mothers.
Immunotoxicant exposures
The PFAS concentrations were measured in all serum samples by
online solid-phase extraction followed by high-pressure liquid
chromatography with tandem mass spectrometry (Haug et al.
2009; Grandjean et al. 2012). The analyses quantified the five
major PFAS, i.e. perfluorohexanesulfonic acid (PFHxS), PFOA,
PFOS, PFNA, and PFDA. Within-batch and between-batch
imprecision levels (coefficients of variation) for all five PFASs
were <3% and 5–6%, respectively, in agreement with excellent
results obtained in regular comparisons organized by the
German Society of Occupational Medicine.
As developmental exposure to polychlorinated biphenyls
(PCBs) can also reduce vaccine responses (Heilmann et al. 2010),
this study also measured maternal serum-PCB concentrations
and used the sum of the three major congeners as an indicator
of the total PCB exposure (Grandjean et al. 2012).
Vaccine antibodies
Focus was maintained on tetanus and diphtheria, as these toxoid
vaccines trigger immune system responses involving both T- and
B-cells (Schatz et al. 1998). Serum concentrations of IgG antibod-
ies were again measured by the Danish vaccine producer (Statens
Serum Institut [SSI], Copenhagen, Denmark) using an enzyme-
linked immunosorbent assay for tetanus (Hendriksen et al. 1988),
while diphtheria antibodies were measured using a standard
Vero cell-based neutralization assay employing two-fold dilutions
(Miyamura et al. 1974). For both assays, calibration was per-
formed using international and local standard antitoxins. We
used the cutoff limit of 0.1 IU/ml for both vaccine antibodies, as
recommended by the SSI, to determine whether antibody con-
centrations could be considered protective.
Statistical methods
Due to skewed distributions, antibody concentrations and serum-
PFAS concentrations were log-transformed (base 2) before enter-
ing the models. We first applied standard multiple regression
analyses, where log-transformed PFAS concentrations at different
ages were included as independent variables one at a time. More
advanced models relied on structural equations (Mogensen et al.
2015a). All analyses were adjusted for age and sex. Joint models
were developed for the combined data that also included the data
from Cohort 3 (Grandjean et al. 2012), where cohort identity
was included as an additional covariate that was allowed to inter-
act with sex, age, and PFAS concentrations. Effects were
expressed as the relative change in the antibody concentration
associated with a doubling in the PFAS concentration. In sensi-
tivity analyses, it was tested whether cesarean section (N¼ 63)
played a role, and likewise possible effects of pre-natal PCB
exposure and duration of breastfeeding were considered.
As previous results on Cohort 3 showed that PFAS concentra-
tions in childhood depended on the duration of breastfeeding (in
months) (Mogensen et al. 2015b), early post-natal serum-PFAS
concentrations were modeled from their dependence on the dur-
ation of breastfeeding in a piece-wise linear model:
log PFASi;a ¼ lþ a exclusivei;a þ b partiali;a þ c nomilki;a
þ Ui þ ei;a
(1)
where log PFASi,a is the log-transformed serum concentration of
child i at age a, while exclusivei,a, partiali,a, and nomilki,a indicate
the number of months that the child was exclusively breastfed,
partially breastfed, and not breastfed at all by age a. The variable
Ui accounts for within-child correlation, i.e. the fact that a child
above the mean at one timepoint will also tend to be higher at
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other time points. The last term ei,a is a random measurement
error. So, at birth, the log transformed serum concentration is
given by the intercept (mþUi), which is allowed to be specific for
each child. During the period of exclusive breastfeeding, the log-
transformed concentration is assumed to change by a slope of a.
Likewise, during partial breastfeeding the slope is b, and after
weaning, the slope is c. This model was fitted to the data from
the two cohorts separately, and a joint model was then fitted
under the assumption that breastfeeding effects were homoge-
neous while allowing the serum-PFAS concentration (m) to
depend on cohort. This part of the model allows, in principle, a
prediction of the serum-PFAS concentration at any given age,
based on the breastfeeding history up to that age. Estimated con-
centrations for age 18 months were then compared with meas-
ured serum concentrations at that age.
A second part of the structural equation model links the mod-
eled exposure to the vaccine antibody concentration at age 5
using a linear regression similar to the standard models used for
observed exposures, i.e.
log antibodyi ¼ h0 þ h1 log PFASi;a þ h2 sexi þ h3 age60i þ ei
(2)
where age60i is the child’s age (months) at the 5-year examination
and here log PFASi,a is the modeled log-transformed concentration
in child i at age a (given by lþ a exclusivei,aþb partiali,aþ c
nomilki,aþUi). In this model, we estimated the effect of a doubling
of the exposure at ages 3, 6, and 12 months. As in the regression
analyses, the calculations allowed for differences between cohorts
by allowing the intercept and the effects of the covariates (age and
sex) to depend on cohort. We focused on the two major PFASs
that showed the strongest associations for pre-natal exposures.
The calculations were carried out for the two cohorts separately
and jointly. As maternal serum in Cohort 5 was not obtained at
childbirth, sensitivity analyses were carried out to assess whether
the number of days between parturition and blood sampling for
PFAS analysis affected the estimated relation between breastfeed-
ing and the child’s PFAS-concentrations. This was done by chang-
ing model (1) for the concentration at birth (a¼ 0) so that it also
depended on the interval (days) between childbirth and blood
sampling, as well as a covariate indicating whether the child was
breastfed, and an interaction term. This way, allowance was made
for the possibility that maternal serum-PFAS concentrations meas-
ured post parturition may have been affected by changes in distri-
bution volume or transfer of PFASs from mother to child via
lactation. The algorithm also allowed for a possible beneficial
effect of breastfeeding on the child’s antibody concentration, as an
additional covariate in model (2) indicated whether the child had
been breastfed for at least 6 months.
Regression analyses were conducted using SAS version 9.4
(SAS Institute, Inc., Cary, NC), while structural equation models
were fitted using the R software, the lava package.
Results
A total of 381 children (77% of 495 cohort members) partici-
pated in the age-5 examinations, and 370 (97%) of these had also
participated at age 18 months. The characteristics of the 349 chil-
dren who provided sufficient serum for analyses at age 5 and the
275 children who additionally provided sufficient serum for anal-
yses at age 18 months are shown in Table 1.
PFOS was by far the most prevalent PFAS in Cohort 5 with a
median age-5 serum concentration of 4.7 ng/ml. PFOS and
PFOA concentrations decreased from age 18 months to age
5 years (Table 1). Moderate correlations were observed between
the concentrations at ages 18 months and 5 years of the same
PFAS (r up to 0.7 after log transformation), though somewhat
stronger between the different PFASs at each age (r up to 0.9 at
age 18 months and up to 0.8 at age 5 years). The close correla-
tions prevented meaningful adjustment for concomitant PFAS
exposures. In regard to the antibody concentrations, they showed
clear decreases from age 18 months to the (pre-booster) examin-
ation at age 5 years (Table 1). At age 5, 152 (44%) children had
antibody concentrations lower than the protective level of 0.1 IU/
ml for diphtheria and 126 (36%) for tetanus.
Multiple regression analyses showed inverse associations
between serum-PFAS concentrations and antibody concentrations
in most analyses (Table 2). In Cohort 5, the strongest inverse
associations were found for tetanus, especially in regard to pre-
natal PFAS exposures. For all three sets of serum analyses, PFOA
showed the strongest associations with lower tetanus antibody
concentrations at age 5. Little difference occurred between the
cohorts, and joint analyses again revealed clear inverse associa-
tions for PFOA. In regard to pre-natal exposures, both PFOS and
PFOA showed clear inverse associations with antibody levels, and
inclusion of the interval between childbirth and maternal blood
sampling in Cohort 5 did not affect the results. Cross-sectional
comparisons in the joint analysis at age 5 showed inverse associa-
tions also for PFNA and PFDA, though in regard to diphtheria
only. The PCB concentration in maternal pregnancy serum cor-
related poorly with the child’s serum-PFAS concentrations
(r between 0.0 and 0.3), similar to previous results (Grandjean
et al. 2012), and adjustment for developmental PCB exposure
had no appreciable effect on the associations for the PFASs.
Likewise, adjustment for cesarean section did not substantially
affect the results.
Table 1. Characteristics of children who contributed serum antibody concentrations at the two follow-up examinations
in Cohort 5.
Age 18 months (N¼ 275) Age 5 years (N¼ 349)
n (%) n (%)
Sex, girls 139 (50.6) 173 (49.6)
Median (25; 75 percentile) Median (25; 75 percentile)
Age (months) 18.5 (18.1; 18.9) 60.4 (59.9; 60.9)
PFOS (ng/ml) 7.1 (4.5; 10.0) 4.7 (3.5; 6.3)
PFOA (ng/ml) 2.8 (2.0; 4.5) 2.2 (1.8; 2.8)
PFHxS (ng/ml) 0.2 (0.1; 0.4) 0.3 (0.2; 0.4)
PFNA (ng/ml) 1.0 (0.6; 1.5) 1.1 (0.8; 1.6)
PFDA (ng/ml) 0.3 (0.2; 0.4) 0.3 (0.2; 0.5)
Tetanus (IU/ml) 1.5 (0.5; 3.0) 0.1 (0.1; 0.3)
Diphtheria (IU/ml) 1.6 (0.8; 3.2) 0.1 (0.1; 0.3)
Duration of exclusive breastfeeding (months) 5 (4; 6)
Duration of mixed breastfeeding (months) 4 (2; 7)
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Duration of breastfeeding is closely associated with the child’s
post-natal PFAS-concentrations (Table 3), even for PFHxS, but
differences between cohorts 3 and 5 were minor. Serum-PFAS
concentrations during infancy were then estimated on the basis
of breastfeeding duration. Estimated serum-PFAS concentrations
extended to age 18 months correlated closely with the measured
serum concentrations in Cohort 5 at this age (Figure 1), thereby
supporting the validity of the calculations. The predicted
concentrations of PFOS and PFOA in early infancy tended to be
inversely associated with the antibody concentrations at age 5
(Table 4), most clearly for PFOA in regard to tetanus, where a
doubled exposure led to a decrease in the antibody concentration
of about 30% at age 5 years. Tendencies were similar in the two
cohorts, whether cohort-specific or based on the joint model that
assumed identical relationships between breastfeeding and PFAS
exposure in the two cohorts. The results presented in Table 4 are
Table 2. Change (in percent) of the pre-booster serum-antibody concentrations at age 5 years associated with a doubling of the serum concentration of major
PFASs at three different times of examination.
Cohort 5 Cohort 3 Joint
Change 95% CI p Change 95% CI p Change 95% CI p
Tetanus
At birth
PFOS 10.84 28.34; 10.94 0.30 10.09 31.78; 18.51 0.45 10.55 24.63; 6.16 0.20
PFOA 22.25 35.25; –6.63 0.007 10.46 28.04; 11.41 0.32 17.59 28.38; –5.17 0.007
PFHxS 11.31 21.72; 0.49 0.060 6.30 15.05; 3.34 0.19 8.24 15.05; –0.89 0.029
PFNA 7.11 26.59; 17.53 0.54 11.16 8.46; 34.98 0.29 3.36 11.02; 20.07 0.67
PFDA 8.40 26.27; 13.79 0.43 2.45 18.39; 16.61 0.79 4.90 17.14; 9.15 0.47
18 months
PFOS 7.027 21.63; 10.30 0.40 8.05 55.26; 89.01 0.82 7.08 21.29; 9.70 0.39
PFOA 16.31 29.04; –1.31 0.034 19.24 59.75; 62.05 0.55 16.47 28.84; –1.96 0.028
PFHxS 2.616 10.08; 5.47 0.51 5.18 51.71; 86.19 0.88 2.65 10.05; 5.36 0.50
PFNA 6.981 21.10; 9.67 0.39 33.79 64.36; 23.01 0.19 9.04 22.43; 6.65 0.24
PFDA 5.780 23.56; 16.13 0.58 14.47 56.88; 69.66 0.65 6.55 23.47; 14.09 0.50
60 months
PFOS 9.076 28.10; 14.98 0.43 11.86 29.79; 10.65 0.28 10.52 24.00; 5.35 0.18
PFOA 25.26 42.63; –2.64 0.031 13.28 31.34; 9.54 0.23 18.75 31.79; –3.21 0.020
PFHxS 4.432 21.26; 15.99 0.65 6.29 17.45; 6.38 0.32 5.74 15.22; 4.81 0.27
PFNA 10.31 24.39; 6.40 0.21 5.87 21.67; 13.12 0.52 8.28 19.06; 3.940 0.18
PFDA 1.756 16.73; 15.91 0.83 13.55 26.18; 1.24 0.071 8.11 18.03; 3.01 0.15
Diphtheria
At birth
PFOS 14.00 31.59; 8.11 0.20 38.64 54.07; –18.04 0.001 24.47 36.90; –9.60 0.002
PFOA 18.93 33.16; –1.66 0.033 16.24 33.43; 5.40 0.13 17.82 29.11; –4.74 0.009
PFHxS 3.33 15.28; 10.30 0.61 6.41 15.62; 3.80 0.21 5.25 12.66; 2.79 0.19
PFNA 4.79 18.21; 34.27 0.71 14.82 30.55; 4.47 0.12 7.38 20.89; 8.43 0.34
PFDA 3.54 23.19; 21.15 0.76 21.73 35.09; –5.63 0.010 14.86 26.33; –1.60 0.029
18 months
PFOS 17.55 0.84; 39.34 0.062 21.21 61.54; 61.40 0.51 15.07 2.49; 35.79 0.096
PFOA 4.19 11.76; 23.02 0.63 30.49 35.31; 163.21 0.46 5.44 10.28; 23.92 0.52
PFHxS 7.85 0.38; 16.76 0.062 12.42 55.25; 71.43 0.70 7.54 0.60; 16.35 0.070
PFNA 24.43 5.72; 46.45 0.009 35.28 64.95; 19.48 0.16 19.18 1.72; 39.62 0.030
PFDA 25.52 2.00; 54.48 0.032 22.87 60.92; 52.24 0.45 20.42 1.29; 46.90 0.067
60 months
PFOS 17.17 8.66; 50.31 0.21 16.02 34.01; 6.87 0.16 1.34 17.05; 17.34 0.88
PFOA 18.31 10.72; 56.78 0.24 6.84 27.26; 19.30 0.57 3.38 14.16; 24.50 0.73
PFHxS 4.26 15.12; 28.08 0.69 4.98 8.25; 20.13 0.48 4.77 6.40; 17.26 0.42
PFNA 8.85 23.95; 9.25 0.32 17.70 32.30; 0.03 0.050 13.06 23.86; –0.72 0.039
PFDA 8.99 23.63; 8.46 0.29 15.96 28.91; –0.66 0.042 12.71 22.66; –1.48 0.028
Table 3. Percentage change in serum-PFAS concentrations per month during exclusive breastfeeding, partial, and none.
Cohort 5 Cohort 3 Joint
Exposure Nursing Change 95% CI p Change 95% CI p Change 95% CI p
PFOS Exclusive 14.76 (13.13, 16.41) <0.001 21.03 (17.02, 25.19) <0.001 15.74 (14.24, 17.26) <0.001
Mixed 6.32 (5.29, 7.37) <0.001 3.26 (0.32, 6.29) 0.030 5.99 (5.00, 6.98) <0.001
None 0.07 (0.50, 0.36) 0.75 0.71 (1.77, 0.35) 0.19 0.2 (0.60, 0.19) 0.31
PFOA Exclusive 16.69 (14.82, 18.60) <0.001 24.05 (19.35, 28.93) <0.001 17.78 (16.05, 19.54) <0.001
Mixed 7.22 (6.04, 8.41) <0.001 5.08 (1.58, 8.71) 0.004 7.01 (5.88, 8.14) <0.001
None 0.8 (0.30, 1.29) 0.002 1.31 (0.04, 2.59) 0.043 0.77 (0.31, 1.23) 0.001
PFHxS Exclusive 23.91 (19.83, 28.12) <0.001 2.95 (8.46, 2.88) 0.31 20.56 (16.68, 24.56) <0.001
Mixed 2.25 (0.07, 4.61) 0.057 11.54 (16.72, 6.04) <0.001 2.1 (0.19, 4.45) 0.073
None 7.91 (8.83, 6.98) <0.001 16.82 (18.70, 14.90) <0.001 7.48 (8.38, 6.56) <0.001
PFNA Exclusive 13.77 (12.05, 15.51) <0.001 20.15 (15.82, 24.65) <0.001 14.55 (12.96, 16.16) <0.001
Mixed 8.55 (7.43, 9.69) <0.001 4.61 (1.37, 7.95) 0.005 8.17 (7.09, 9.25) <0.001
None 0.91 (0.45, 1.37) <0.001 1.29 (2.44, 0.12) 0.030 0.66 (0.24, 1.09) 0.002
PFDA Exclusive 11.5 (9.83, 13.19) <0.001 14.51 (8.98, 20.32) <0.001 11.45 (9.85, 13.08) <0.001
Mixed 9.64 (8.51, 10.78) <0.001 5.03 (0.73, 9.51) 0.021 9.49 (8.38, 10.61) <0.001
None 4.21 (3.73, 4.69) <0.001 0.29 (1.24, 1.86) 0.71 4.05 (3.58, 4.51) <0.001
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adjusted for duration of breastfeeding, but the direct effects of
breastfeeding on antibody concentrations tended to be weakly
negative, and the impact on the regression coefficients for the
PFASs was minor.
Discussion
The present prospective study aimed at exploring the role of
PFAS exposure in infancy in regard to responses to routine
childhood immunizations in terms of antibody concentrations
measured at age 5 years, i.e. four years after the most recent
(third) vaccination. While greater vulnerability to immunotoxi-
cants is suspected during early maturation of the adaptive
immune system, previous studies have not been able to elucidate
this possibility, as blood samples are difficult to collect from
healthy infants. While serum-PFAS concentrations tend to be
quite stable in adults (Zhang et al. 2013), the concentrations in
children are much more variable, possibly because of age-
dependent changes in exposure sources (Kato et al. 2009;
Lindstrom et al. 2011). Accordingly, our results showed only
(a)
(b)
Figure 1. Serum concentrations of (a) PFOA and (b) PFOS at age 18 months, as calculated from neonatal concentration and the duration of breastfeeding (vertical
scale) and compared to the measured concentration (horizontal scale).
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modest correlations between serum-PFAS concentrations at birth
and at ages 18 months and 5 years, likely due to differences in
the transfer via breast-feeding (Mogensen et al. 2015b). For sev-
eral industrial chemicals, breast milk is known to serve as an
exposure pathway (Grandjean and Jensen 2004; Stefanidou et al.
2009); our observation that serum-PFAS concentrations in
infants increase substantially with the duration of breast-feeding
is in accordance with this notion.
In order to estimate PFAS concentrations over time, single-
compartment toxicokinetic models have been successfully
applied, e.g. to calculate past serum-PFOA concentrations after
cessation of exposure (Seals et al. 2011) and serum-PFAS profiles
in children exposed from breastfeeding (Verner et al. 2016).
Thus, the present study included both PFAS concentrations
measured in age 18-month blood samples, and the study also uti-
lized information on the duration of exclusive breastfeeding to
calculate profiles of serum-PFAS concentrations during infancy.
Such calculations assume that each child received the same
daily amount of milk in regard to body weight and that the
transfer was constant throughout the duration of exclusive
breastfeeding without major differences in age-dependent
changes in the distribution volume. Partial breastfeeding was
taken into account, but seemed to be of negligible importance.
Despite the reservations, the validity of the calculations is sup-
ported by the close correlation of observed and calculated serum
concentrations at age 18 months (Figure 1). Nonetheless, the esti-
mated serum-PFAS concentrations in infancy likely involve some
random imprecision, thus causing a potential bias toward the
null (Grandjean and Budtz-Jorgensen 2010) and thereby a pos-
sible underestimation of the impact of PFAS exposures at infancy
on adaptive immune system functions. The close correlation seen
in Figure 1 suggests that this bias is small.
As a further consideration, while breastfeeding may transfer
toxicants to the infant, it is considered advantageous to the
developing immune system (Kramer et al. 2007). However,
although almost all studies on benefits from breastfeeding have
ignored any possible bias from effects in the opposite direction
from immunotoxicants transferred via human milk (Grandjean
and Jensen 2004; Grandjean et al. 2010), thereby potentially lead-
ing to residual negative confounding (Choi et al. 2008). As before
(Grandjean et al. 2012), we were unable to detect any important
benefit on the two antibody concentrations associated with the
duration of exclusive breast-feeding.
In agreement with our previous studies (Grandjean et al.
2012; Mogensen et al. 2015a), the present study confirmed the
inverse associations with pre-natal exposures for both toxoid
antibodies, and our findings now extend these observations by
adding information on exposures during early childhood.
Associations for diphtheria and tetanus differ somewhat, perhaps
because the diphtheria toxoid is considered a weaker antigen
than tetanus and because the associations may depend on relative
levels of exposure as well as possible differences in age-dependent
vulnerability. Maintenance of the antibody concentrations in
serum may be a vulnerable target, but previous studies have also
documented an inverse association of serum-PFAS concentra-
tions with the short-term response to vaccinations both in chil-
dren and in adults (Grandjean et al. 2012; Looker et al. 2014;
Kielsen et al. 2016). Overall, these findings are in accordance
with immunotoxic effects demonstrated in laboratory models
(National Toxicology Program 2016) including in vitro studies of
human immune cells (Corsini et al. 2012). Still, the detailed
mechanisms involved are unclear at present.
The adaptive immune system is at first dominated by TH2
responses, and TH1 responses mature during infancy, thereby
allowing proper responses to routine immunizations (Romagnani
2014). In regard to TH2-related allergy, increased odds of asthma
in children were reported at elevated PFAS exposures (Dong et al.
2013), although this finding has not been replicated (Humblet
et al. 2014). Our own studies (i.e. Timmermann et al. 2017) sug-
gested that serum-PFAS concentrations at age 5 years were associ-
ated with increased odds of asthma only among the children who
had not yet been vaccinated against measles, mumps, and rubella
(MMR), while the association was reversed among MMR-vacci-
nated children. Although inhibition of antibody responses, per-
haps associated with increased risk of allergy development, could
represent a change in the TH1/TH2 balance (Dong et al. 2011),
the relative role of the immune system components is complex.
The lack of clear evidence on PFAS-associated allergy may in part
be due to uncontrolled and variable allergen exposures and the
absence of outcome variables that are as well-defined and standar-
dized as are vaccine-induced antibodies.
Our previous results show that an insufficient vaccination
response may be remedied at least in part by an additional
booster (Grandjean et al. 2017). However, while these deficient
antibody responses do not represent an irreparable insult, the
boosters may not remedy any additional immune dysfunctions
due to PFAS exposures. Among possible consequences of insuffi-
cient responses to childhood immunizations could be an
increased risk of infectious diseases other than those that the vac-
cines aim to protect against. Thus, increased incidence of
Table 4. Effect of doubling in predicted serum concentration of PFOA and PFOA at different ages (in months) with adjustment for differences in dependence on
breastfeeding in the two cohorts.
Vaccine/ Cohort 5 Cohort 3 Joint
Exposure Age Change 95% CI p Change 95% CI p Change 95% CI p
Tetanus
PFOS 3 20.03 (38.88, 4.62) 0.10 24.75 (53.37, 21.42) 0.24 21.16 (37.60, 0.38) 0.046
6 13.13 (30.52, 8.62) 0.22 27.74 (46.26, 2.86) 0.031 18.81 (32.06, 2.99) 0.022
12 6.58 (22.62, 12.78) 0.48 16.92 (32.17, 1.77) 0.073 11.50 (22.91, 1.60) 0.083
PFOA 3 32.63 (46.72, 14.82) 0.001 23.03 (48.45, 14.94) 0.20 30.35 (43.20, 14.59) 0.001
6 24.81 (38.43, 8.19) 0.005 28.17 (45.08, 6.07) 0.016 26.06 (37.01, 13.20) <0.001
12 16.92 (30.11, 1.25) 0.035 17.75 (32.01, 0.51) 0.044 17.31 (27.25, 6.02) 0.004
Diphtheria
PFOS 3 0.90 (24.02, 29.26) 0.95 54.36 (73.91, 20.16) 0.006 15.30 (33.08, 7.21) 0.17
6 3.35 (17.16, 28.95) 0.77 27.40 (47.47, 0.34) 0.052 7.32 (22.79, 11.25) 0.42
12 3.65 (13.90, 24.78) 0.71 2.70 (22.31, 21.85) 0.81 1.12 (12.38, 16.69) 0.88
PFOA 3 12.36 (30.61, 10.69) 0.27 31.05 (56.20, 8.54) 0.11 16.87 (32.35, 2.15) 0.079
6 6.42 (23.28, 14.14) 0.51 16.46 (37.69, 12.02) 0.23 9.73 (23.41, 6.39) 0.22
12 3.88 (18.97, 14.02) 0.65 2.63 (16.87, 26.69) 0.81 1.28 (13.54, 12.72) 0.85
JOURNAL OF IMMUNOTOXICOLOGY 193
common cold and gastroenteritis in 3-year-olds were recorded in
relation to higher maternal serum PFOA concentrations during
pregnancy (Granum et al. 2013), and a greater incidence of infec-
tion was also linked with lower vaccine antibody concentrations
(Pennings et al. 2016). Similarly, the incidence of disease with
high fever in small children was positively associated with the
mother’s serum-PFAS concentrations in early pregnancy
(Dalsager et al. 2016). While serum concentrations of PFOS and
PFOA during pregnancy were apparently not associated with the
total hospitalization rate for infectious diseases in school-age
children (Fei et al. 2010), quality concerns regarding the
serum-PFAS analyses in this cohort (Bach et al. 2015) questions
the validity of this report.
The National Toxicology Program recently concluded that
both PFOS and PFOA are presumed immune hazards for
humans (National Toxicology Program 2016), while acknowledg-
ing that the epidemiological studies are unable to attribute PFAS
associations to individual compounds. PFAS exposures in the
Faroes are quite similar to those in the USA (CDC 2015), but
inter-correlations between serum-PFAS concentrations pre-
natally and at different ages make it difficult to determine accur-
ately the possible age-dependent roles of individual PFASs in
regard to immune function outcomes.
Conclusions
As PFASs are excreted in human milk, serum concentrations in
infancy can be estimated from serum analyses at birth and the
duration of exclusive breastfeeding. Both pre-natal exposures and
estimated serum levels in early infancy showed clear inverse asso-
ciations with antibody concentrations against two toxoid vaccines
at age 5 years, while associations with PFAS concentrations at
ages 18 months and 5 years were weaker. Given that the adaptive
immune system undergoes crucial maturation during infancy,
the results support the high vulnerability of the developing
immune system. Thus, the present study extends the evidence on
PFAS-associated deficient antibody responses in children and
emphasizes that infants may need particular protection as a
highly vulnerable sub-population.
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